Respiratory Antiviral Treatment Market Size to Hit US$ 5.4 Billion by 2030
According to latest report, the global respiratory antiviral treatment market reached value at US$ 3 Bn in 2020 and predicted to hit US$ 5.4 billion by 2030.
Respiratory Antiviral Treatment Market growth is expanding at a CAGR of 6.1% from 2021 to 2030. The growth of the global respiratory antiviral treatment market can be ascribed to rise in prevalence of respiratory viral diseases and ongoing clinical trials, and increase in FDA approvals.
Antiviral drugs are therapeutics that prevent the development and replication of virus without affecting host cells. These drugs do not destroy their target virus, as it is an obligatory intracellular parasite. Instead, these inhibit their propagation by deactivating the viral enzymes. Different types of drugs are used in the treatment of respiratory viral diseases including ribavirin, aciclovir, oseltamivir, zanamivir amantadine, and amantadine.
Outbreak of Pandemic Respiratory Viral Diseases, Ongoing Clinical Trials, and Increase in FDA Approvals to Drive Global Market
The rise in prevalence and incidence of respiratory viral diseases such as influenza and bronchiolitis across the globe is a key factor driving the global respiratory antiviral treatment market. The WHO estimated that around 3 million to 5 million influenza cases occur globally every year; 250,000 to 500,000 of these result in deaths. Hence, increase in incidence of influenza continues to encourage the use of influenza medication, thereby driving the market. According to the CDC, COVID-19 pandemic resulted in over 814,000 deaths globally, as of August 2020.
Ongoing clinical trials for respiratory viral disease treatment, drugs, pipeline products, and safety and efficacy studies have increased over the past few years. Moreover, marketing approvals for antiviral therapies and drugs by the FDA and other authorities in different regions are expected to boost the growth of the global respiratory antiviral treatment market. In October 2019, Genentech, Inc. received the U.S. Food and Drug Administration (FDA) approved for Xofluza (Baloxavir Marboxil) for people at high risk of developing influenza-related complications.
Healthcare Facilities Increase Influenza and COVID-19 Testing Due to Ongoing Flu Season
The coronavirus (COVID-19) outbreak has sparked concern among individuals suffering from influenza. Due to similarities in symptoms, healthcare institutes are increasing awareness about the differences in symptoms. Though influenza and COVID-19 are both contagious respiratory illnesses, they are caused by different viruses. This confusion has created revenue opportunities for companies in the respiratory antiviral treatment market, since infected individuals are seeking professional help from doctors to identify the symptoms.
Influenza is a serious medical issue in western countries. A second wave of COVID-19 in European countries is likely to compromise healthcare facilities. Hence, healthcare professionals are identifying people at high risk of acquiring influenza and COVID-19, and are recommending preventive measures to minimize the pressure in healthcare facilities.
RSV-associated Clinical Trails Holds Promising Potentials for Development of Bronchiolitis Antivirals
Innovations in the treatment of respiratory syncytial virus (RSV) infection hold promising potentials for the bronchiolitis treatment. For instance, Ark Biosciences— a biotech company specializing in therapeutics for viral infections and respiratory illnesses has announced a successful completion of the phase 2 proof-of-concept study for Ziresovir (AK0529), which is an antiviral agent. Bronchiolitis has led to several hundreds of thousands of deaths worldwide, especially of children under five years of age. Hence, companies in the respiratory antiviral treatment market are increasing their research capabilities to develop therapeutics for bronchiolitis in infants.
Current antiviral agents developed by companies in the respiratory antiviral treatment market are found to have clinical benefits but are not licensed by healthcare institutions. Companies are increasing efforts to develop antivirals that are effective in reducing signs and symptoms of bronchiolitis in infants.
Antiviral Therapies Emerge as Alternative to Influenza Vaccines in High-risk Patients
The antiviral treatment is being highly preferred to shorten the duration of influenza symptoms. Moreover, these antivirals help to decrease the length of hospitals stays and minimizes the risk of complications in patients. As suggested by the CDC (Centers for Disease Control and Prevention), antiviral therapies help to improve medical outcomes in high-risk patients. As such, antiviral chemoprophylaxis is gaining increased popularity for influenza prevention and is being used as an adjunct to vaccination. Companies in the respiratory antiviral treatment market are boosting their output capacity to produce antiviral chemoprophylaxis meant for high-risk patients who cannot receive vaccination due to medical reasons.
Since high-risk patients such as pregnant women are susceptible to contraindications by vaccines, companies in the respiratory antiviral treatment market are increasing awareness about antiviral chemoprophylaxis to treat influenza. Patients with insufficient immune response are also recommended with antiviral chemoprophylaxis.
Report Highlights
In terms of drug class, the global respiratory antiviral treatment market has been divided into nucleoside analogs, neuraminidase inhibitors, ion channel blockers, and fusion protein inhibitors. The neuraminidase inhibitors segment dominated the global respiratory antiviral treatment market in 2019. This trend is likely to continue during the forecast period. Oseltamivir is first-line treatment for several respiratory viral diseases such as influenza. It is available as a prodrug oseltamivir phosphate and is converted by the liver to active metabolite oseltamivir carboxylate. The mechanism of action of oseltamivir carboxylate and other NAIs is to interfere with the release of influenza viral particles from infected host cells by binding to influenza viral neuraminidase, resulting in reduced spread of influenza viruses in the respiratory tract. This factor is projected to drive the segment.
Nucleoside analogs was the second largest segment in terms of market share in 2020. The growth of the segment can be attributed to increase in demand for nucleoside analogs, owing to rise in occurrence of seasonal influenza and RSV infection.
In terms of disease type, the global respiratory antiviral treatment market has been categorized into influenza, bronchiolitis, pneumonia, upper respiratory tract infections (URTIs), and others (measles, etc.). The influenza segment accounted for prominent share of the global respiratory antiviral treatment market in 2020, owing to rise in number of patients and awareness about the disease. According to the World Health Organization, around 1 billion influenza cases are reported globally each year, and 300,000 to 500,000 deaths occur due to influenza in every year.
In terms of distribution channel, the global respiratory antiviral treatment market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment led the global respiratory antiviral treatment market in terms of revenue in 2020. The trend is expected to continue during the forecast period. Rapid increase in the number of hospitals and wide range of services available in multispecialty hospitals are likely to augment the segment during the forecast period. The surge in the number of patients opting for retail pharmacies due to a large number of product brands available at discounted prices at these pharmacies is projected to drive the retail pharmacies segment during the forecast period.
North America dominated the global respiratory antiviral treatment market in 2020, followed by Europe. North America’s large market share can be ascribed to increase in the number of people with respiratory viral diseases, new product launches, and presence of major players in the region. According to the CDC, around 5.6 million patients are suffering from COVID-19 in the U.S., as of August 2020.
The respiratory antiviral treatment market in Asia Pacific is anticipated to expand at a high CAGR from 2021 to 2030. This can be ascribed to the presence of developing countries with commercial hubs, expanding business organizations, rise in awareness about respiratory antiviral, improving healthcare infrastructure, and increase in investments by companies in their technical aspects.
Competitive Landscape
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2017 to 2019.
The analysts have provided a comprehensive analysis of the competitive landscape of the global respiratory antiviral treatment market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation expected to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users) and other segments.
Key players operating in the global market include F. Hoffmann-La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company Limited, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Mylan, Inc., Merck & Co., Inc., and AstraZeneca plc.
Market Segmentation
By Drug Class
By Disease Type
By Distribution Channel
By Region
This report focuses on respiratory antiviral treatment market includes crucial information on market share, market size, and growth rate for the forecast period 2021 to 2030 at the global level, regional level and company level. From a global perspective, this report represents overall respiratory antiviral treatment market size by analyzing historical data and future prospect. The study highlights deep analysis on the major drivers of the market, restraints, and challenges to help the business owners, suppliers, and marketing personnel in planning effective strategies for the forecast period. This will help the business and manufacturers to lead the market and gain prominent position in future. The report also presents vital information through graphical representation on factors like table, charts, and statistics. The study includes drivers and restraints of the global respiratory antiviral treatment market.
The research not only conducts forecasts in terms of value, but also evaluates the market on the basis of essential parameters, such as Year-on-Year (Y-o-Y) growth. This helps providers to recognize the future opportunities as well predictability of the market.
In order to understand and assess opportunities in this market, the report is categorically divided into five key sections on the basis of segments. The report analyzes the global market in terms of value (US$ dollers) and volume (Million Units).
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Every segment is further sub-segmented into several sub-segmented that are deeply analyzed by experts to offer valuable information to the buyers and market players. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Regional Analysis
The research report includes a detailed study of regions of North America, Europe, China, Japan and Rest of the World. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2017 to 2030. These analyses will help the reader to understand the potential worth of investment in a particular region.
The report provides in-depth segment analysis of the global respiratory antiviral treatment market, thereby providing valuable insights at macro as well as micro levels. Analysis of major countries, which hold growth opportunities or account for significant share has also been included as part of geographic analysis of the respiratory antiviral treatment market.
The report includes country-wise and region-wise market size for the period 2017-2030. It also includes market size and forecast by segments in terms of production capacity, price and revenue for the period 2017-2030.
In this study, the years considered to estimate the market size of respiratory antiviral treatment are as follows:
Research Methodology
The research methodology adopted by analysts for compiling the global respiratory antiviral treatment market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global respiratory antiviral treatment market.
The study objectives of this report are:
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers